Disease-Free Survival
Figure 2 · Panel Overall_Cohort_DFS
Panel Overall_Cohort_DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Sumit Gupta, Rachel E Rau, John A Kairalla, Karen R Rabin, Cindy Wang, Anne L Angiolillo, Sarah Alexander, Andrew J Carroll, Susan Conway, Lia Gore, Ilan Kirsch, Holly R Kubaney, Amanda M Li, Jennifer L McNeer, Olga Militano, Tamara P Miller, Yvonne Moyer, Maureen M O'Brien, Maki Okada, Shalini C Reshmi, Mary Shago, Elizabeth Wagner, Naomi Winick, Brent L Wood, Tara Haworth-Wright, Faraz Zaman, Gerhard Zugmaier, Sue Zupanec, Meenakshi Devidas, Stephen P Hunger, David T Teachey, Elizabeth A Raetz, Mignon L Loh
N Engl J Med 392(9) 875-891
BACKGROUND: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes. METHODS: We conducted a phase 3 trial involving children with newly diagnosed standard-risk B-cell ALL who had an average or higher risk of relapse. Patients were randomly assigned to receive chemotherapy alone or chemotherapy plus two nonsequential 28-day cycles of blinatumomab. The primary end point was disease-free survival. RESULTS: The data and safety monitoring committee reviewed the results from the first interim efficacy analysis, which included 1440 patients who had undergone randomization (722 to chemotherapy alone and 718 to blinatumomab and chemotherapy) and recommended early termination of randomization. At a median follow-up of 2.5 years, the estimated 3-year disease-free survival (±SE) was 96.0±1.2% with blinatumomab and chemotherapy and 87.9±2.1% with chemotherapy alone (difference in restricted mean survival time, 72 days; 95% confidence interval, 36 to 108; P<0.001 by stratified log-rank test). The estimated 3-year disease-free survival among patients with an average relapse risk was 97.5±1.3% with blinatumomab and chemotherapy and 90.2±2.3% with chemotherapy alone; among those with a higher relapse risk, the corresponding values were 94.1±2.5% and 84.8±3.8%. Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare during blinatumomab cycles, but the overall incidence of nonfatal sepsis and catheter-related infections was significantly higher among patients with an average relapse risk who had been assigned to receive blinatumomab and chemotherapy than among those assigned to receive chemotherapy alone. CONCLUSIONS: Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of Health and others; AALL1731 ClinicalTrials.gov number, NCT03914625.).
1 个 Figure · 6 个 KM 面板
Figure 2:. Outcomes according to randomization. Panel A shows the comparison of 3-year disease-free survival (DFS) (top row), overall survival (OS) (middle row) and cumulative incidence of relapse (CIR) (bottom row) for the overall randomized cohort (left column), randomized SR-Avg patients (middle column) and randomized SR-High patients (right column). Panel B shows the comparison of the 3-year DFS, OS, total CIR and CIR by relapse site among the overall randomized cohort, SR-Avg group, and SR-High group. Note that OS and CIR were not protocol-specified formal endpoints. Widths of intervals were not adjusted for multiplicity and thus for non-primary analyses should not be used in place of hypothesis testing.
Figure 2 · Panel Overall_Cohort_DFS
Panel Overall_Cohort_DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel SR-Avg_DFS
Panel SR-Avg_DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel SR-High_DFS
Panel SR-High_DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel Overall_Cohort_OS
Panel Overall_Cohort_OS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel SR-Avg_OS
Panel SR-Avg_OS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel SR-High_OS
Panel SR-High_OS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。